Beam Therapeutics gained agency agreement to use a biomarker‑based endpoint evaluated over one year to support an accelerated approval filing for BEAM‑302 in alpha‑1 antitrypsin deficiency (AATD). The company said the FDA accepted biomarkers predictive of clinical benefit, allowing a potential accelerated path while a confirmatory trial proceeds. Beam reported early phase signals and investor interest, and the regulatory alignment underscores the agency’s evolving approach to genetic medicines and biomarker endpoints.